BioCrossroads, an Indianapolis-based not-for-profit, is cataloging Indiana businesses offering contract services to pharmaceutical
and biotechnology companies, and discovering many small firms operating in relative obscurity.
Eli Lilly and Co. has agreed to settle the State of South Carolina’s lawsuit that claimed Lilly improperly marketed the antipsychotic
drug Zyprexa, according to Bloomberg News.
Dow AgroSciences could boost its market share in genetically altered corn almost overnight by inventing a perennial corn.
But investors might not have the patience.
Fishers development officials hope to create a huge cluster of medical and research facilities near Interstate 69’s Exit
10, near St. Vincent Medical Center Northeast, but local real estate experts disagree about the amount of potential demand
for such a development.
Health reform that would cover millions of uninsured Americans would theoretically send a flood of new
patients to physicians. Yet in Indiana and nationwide, there’s already a shortage of doctors.
Researchers at IUPUI have been awarded more than $22.3 million in grants by the National Institutes of Health, according to
U.S. Rep. Andre Carson. The money is part of a $5 billion program that was part of the federal stimulus bill approved earlier
this year, and will fund medical research across the country.
The Indiana Division of Aging wants to change Medicaid rates to nursing homes to reward quality care and penalize the lack
of it, leaving the industry divided over whether to support the groundbreaking rule or to seek revisions and a slower phase-in.
Officials of Purdue University and Dow AgroSciences unveiled a collaboration Wednesday in which the Indianapolis-based company
will become one of the largest tenants at the Purdue Research Park in West Lafayette.
Six hospital systems, including three in Indiana, have agreed to pay the federal government $8.3 million to settle a whistleblower
lawsuit alleging the hospitals deliberately overcharged Medicare for routine back surgeries.
Connecticut officials say Eli Lilly and Co. has agreed to a $25 million settlement with the state over claims the drug maker
marketed its anti-psychotic drug, Zyprexa, for unapproved uses and harmed patients.
With its financial performance exceeding expectations, St. Francis Hospital & Health Centers will resume construction on a $265 million, 221-bed patient tower at its Indianapolis campus, the hospital system announced Thursday.
The stitching together of doctors and hospitals—two groups that historically have kept each other at arm’s length—is
a trend picking up speed locally and nationally and could accelerate even further if Congress passes health care reform.
Most business groups cheered when Sen. Max Baucus, D-Mont., introduced a health reform bill with no so-called public option,
a controversial government-run insurance plan for working adults. But there’s a big group that would like
to see it back on the table—hospitals.
The tool the administration is using to measure waste shows that expenses in Indianapolis might be low enough
not to get whacked. But the region isn’t performing so well that it’s likely to get much praise, either.
A decision by a federal judge in Indianapolis to turn back a patent challenge to Eli Lilly and Co.’s Evista marks a major
victory for the company, says an analyst who closely follows the pharmaceutical industry.
A federal judge in Indianapolis turned back a patent challenge to Eli Lilly and Co.’s drug Evista, the company announced
late yesterday.
A new group expected to develop the orthopedic implants industry in Warsaw will be able to proceed now that Indianapolis-based
Lilly Endowment Inc. is putting $7 million behind it, according to an announcement this morning.
Health insurer WellPoint said today that it may trim some more jobs as part of a push to become more efficient next year.
Eli Lilly and Co. has agreed to confidential terms to settle lawsuits brought by seven states alleging the company illegally
marketed bestselling antipsychotic drug Zyprexa, Bloomberg News reported today.
Biotechnology company Adolor Corp. said yesterday that it bought exclusive worldwide rights to Eli Lilly and Co.’s OpRA
III drug candidate, which has a range of potential uses.
